Citation Impact
Citing Papers
Pharmacokinetics and Pharmacodynamics of IFN-β1a in Healthy Volunteers
2000
Metabolic Syndrome: Treatment of Hypertensive Patients
2007
Treatment of multiple sclerosis with Copolymer-1 (Copaxone®): implicating mechanisms of Th1 to Th2/Th3 immune-deviation
1998
The Triad of Sleep Apnea, Hypertension, and Chronic Kidney Disease: A Spectrum of Common Pathology
2016 Standout
Estimated Glomerular Filtration Rate and Urinary Albumin Excretion Are Independently Associated with Greater Arterial Stiffness
2007
C-reactive protein is associated with renal function abnormalities in a non-diabetic population
2003
Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension
2010 Standout
Cladribine and progressive MS
2000
Proteinuria: Its clinical importance and role in progressive renal disease
2000
Cardiac autophagy is a maladaptive response to hemodynamic stress
2007 Standout
Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents
2017 Standout
Obesity and inflammation: the linking mechanism and the complications
2016 Standout
Home, Clinic, and Ambulatory Blood Pressure Monitoring in Children with Chronic Renal Failure
2003
PROTEINURIA AFTER RENAL TRANSPLANTATION AFFECTS NOT ONLY GRAFT SURVIVAL BUT ALSO PATIENT SURVIVAL
2001
Effect of metabolic syndrome or type II diabetes mellitus on the occurrence of recurrent vascular events in hypertensive patients
2008
Chronic kidney disease
2011 Standout
Herbal Medicinals
1998 Standout
Multiple sclerosis
2008 Standout
2007 Guidelines for the Management of Arterial Hypertension
2007 Standout
Structural and functional features of central nervous system lymphatic vessels
2015 StandoutNature
Comparison of ambulatory blood pressure and Task Force criteria to identify pediatric hypertension
2006
Panax ginseng and Panax quinquefolius: From pharmacology to toxicology
2017 Standout
Cardiomyocyte apoptosis in hypertensive cardiomyopathy
2003
The Metabolic Syndrome and Cardiovascular Risk
2010 Standout
Immunopathology of multiple sclerosis
2015 Standout
Abolition of Hypertension-Induced End-Organ Damage by Androgen Receptor Blockade in Transgenic Rats Harboring the Mouse Ren-2 Gene
2002
Tuberous sclerosis
2008 Standout
Treatment of Hypertension in Patients 80 Years of Age or Older
2008 Standout
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
2006 Standout
The role of oxidative stress in the pathogenesis of multiple sclerosis: The need for effective antioxidant therapy
2004 Standout
Insulin-like Growth Factor I as aÈCardiac Hormone: Physiological and Pathophysiological Implications in Heart Disease
1999
Insulin and insulin resistance:
2004 Standout
Management of Chronic Kidney Disease Patients in the Intensive Care Unit: Mixing Acute and Chronic Illness
2017 Standout
Screening, Monitoring, and Treatment of Albuminuria
2006
Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies
2009 Standout
Multiple Sclerosis
2000 Standout
Essential Hypertension, Progressive Renal Disease, and Uric Acid
2005
Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity
2001
An automated tool for detection of FLAIR-hyperintense white-matter lesions in Multiple Sclerosis
2011 Standout
Pathophysiology of the lymphatic drainage of the central nervous system: Implications for pathogenesis and therapy of multiple sclerosis
2009
Herbal Medicines and Perioperative Care
2001 Standout
Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
2013 Standout
Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study
2007
Interactions Between Herbal Medicines and Prescribed Drugs
2001 Standout
Protein therapeutics: a summary and pharmacological classification
2007 Standout
External validity of randomised controlled trials: “To whom do the results of this trial apply?”
2005 Standout
Prediabetes: a high-risk state for diabetes development
2012 Standout
Current role of vigabatrin in infantile spasms
2007
Obstructive Sleep Apnea Is Associated With Increased Urinary Albumin Excretion
2007
Multiple sclerosis
2002 Standout
Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
2020 Standout
Prediction of Cardiovascular Events and All-Cause Mortality With Arterial Stiffness
2010 Standout
Kidney Disease as a Risk Factor for Development of Cardiovascular Disease
2003 Standout
Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
1998 Standout
Levels of Ambrosia pollen in the atmospheric spectra of Catalan aerobiological stations
2000
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial
2010 Standout
Non-diabetic microalbuminuria, endothelial dysfunction and cardiovascular disease
2001
Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus
2016 Standout
Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients
2009 Standout
Complementary/Alternative Medicine Use in a Comprehensive Cancer Center and the Implications for Oncology
2000 Standout
Cascade Processes of Metallo Carbenoids
1996 Standout
Ragweed (Ambrosia) sensitisation rates correlate withthe amount of inhaled airborne pollen. A 14-year studyin Vienna, Austria
2000
[1,2,3]Triazoloazine/(Diazomethyl)azine Valence Tautomers from 5‐Azinyltetrazoles
1978
Ragweed pollen: The aeroallergen is spreading in Italy
1998
Passiflora: a review update
2004 Standout
Allergenic pollen and pollen allergy in Europe
2007 Standout
European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
2001
The Metabolic Syndrome
2008 Standout
2007 ESH‐ESC Guidelines for the management of arterial hypertension
2007
Works of G. Piazza being referenced
Insulin-like growth factor 1 and sodium???lithium countertransport in essential hypertension and in hypertensive left ventricular hypertrophy
1993
Influence of the metabolic syndrome on aortic stiffness in never treated hypertensive patients
2005
Microalbuminuria, renal dysfunction and cardiovascular complication in essential hypertension
1996
Influence of metabolic syndrome on hypertension‐related target organ damage
2005
Relationships between 24 h blood pressure load and target organ damage in patients with mild-to-moderate essential hypertension
2001
Scotopic threshold response changes after vigabatrin therapy in a child without visual field defects: a new electroretinographic marker of early damage?
2004
Value of Home Blood Pressures as Predictor of Target Organ Damage in Mild Arterial Hypertension
2002
Relationship between albumin excretion rate and aortic stiffness in untreated essential hypertensive patients
2004
Endothelium-derived factors in microalbuminuric and nonmicroalbuminuric essential hypertensives
2000
Acute hypokalemic myopathy due to chronic licorice ingestion: report of a case
1983
Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis.
1996
Deuteriation of diazoacetone
1969
Ragweed evidence in Brianza (a hilly area North to Milan)
1992
2002